Fluidigm

Standard BioTools Inc. engages in the provision of biotechnology tools and services for clinical research. It sells preparatory and analytical instruments for mass cytometry, polymerase chain reaction, library prep, single cell genomics, and consumables including integrated fluidic circuits (IFCs), assays, and reagents. The company was founded by Stephen D. Quake and Gajus Vincent Worthington on May 19, 1999 and is headquartered in South San Francisco, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

2019 Gold Award for Best New Product in Cell Biology Awarded to Fluidigm 2019 Gold Award for Best New Product in Cell Biology Awarded to Fluidigm

Fluidigm Receives Life Science Industry Award for the Maxpar Direct Immune Profiling System

SOUTH SAN FRANCISCO, Calif., Nov.  20, 2019  (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ: FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced the pricing of $50 million aggregate principal amount of 5.25% convertible senior notes due 2024 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Fluidigm also granted the initial purchasers of the notes a 13-day option to purchase up to an additional $5 million aggregate principal amount of the notes. The sale of the notes is expected to close on November 22, 2019, subject to customary closing conditions.

Fluidigm Corporation Announces Pricing of Private Offering of $50 Million of 5.25% Convertible Senior Notes

SOUTH SAN FRANCISCO, Calif., Nov.  20, 2019  (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it intends to offer, subject to market conditions and other factors, $45 million of aggregate principal amount of convertible senior notes due 2024 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Fluidigm also intends to grant the initial purchasers of the notes a 13-day option to purchase up to an additional $5 million aggregate principal amount of the notes.

Fluidigm Corporation Announces Proposed Private Offering of $45 Million of Convertible Senior Notes

The lab-instrument developer reported that sales of its leading growth product declined from the third quarter of 2018. Is competition to blame?

Fluidigm Shocks Investors with Worrisome Trend

Scholar Rock Holding Corp

Falling knives are stocks whose share price has fallen more than 59% over the past year, drawing interest from investors as these securities can deliver huge rewards if they rebound.

Analysts See 2 Falling Knives Bouncing Back

The lab instrument developer was crushed after a disappointing quarterly report. Investors are right to worry.

Here's Why Fluidigm Stock Lost as Much as 54.2% Today

Fluidigm Corporation (FLDM) CEO Chris Linthwaite on Q3 2019 Results - Earnings Call Transcript

Fluidigm (FLDM) delivered earnings and revenue surprises of 0.00% and -8.15%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Fluidigm (FLDM) Reports Q3 Loss, Misses Revenue Estimates

Fluidigm (FLDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Fluidigm (FLDM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Delivering automated RNA workflows to significantly reduce cost per sample and hands-on time using microfluidics technology Delivering automated RNA workflows to significantly reduce cost per sample and hands-on time using microfluidics technology

Fluidigm Showcases RNA Sequencing Innovations Using Microfluidics Technology at the 2019 American Society of Human Genetics (ASHG) Meeting

The volatile stock still has potential, but investors need the proper perspective for the slow-growing hardware business.

The Single Most Important Thing for Fluidigm Shareholders to Watch

Powering industry-leading CyTOF technology to deliver new insights in translational and clinical research Powering industry-leading CyTOF technology to deliver new insights in translational and clinical research

Fluidigm Becomes the First Company to Enable 50-Plex Cytometry Panels with the Release of Seven New Metal Antibody Labels

Industry-Leading CyTOF Technology Recognized at the 18th Annual HUPO World Congress for Delivering Unprecedented Proteomic Insight at Single-Cell Resolution Industry-Leading CyTOF Technology Recognized at the 18th Annual HUPO World Congress for Delivering Unprecedented Proteomic Insight at Single-Cell Resolution

CyTOF Inventors Receive Prestigious Science and Technology Award from the Human Proteome Organization (HUPO)

SOUTH SAN FRANCISCO, Calif., Sept.  10, 2019  (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it has filed new legal action in the United States District Court for the Northern District of California seeking to stop the infringement of its patented technology by IONpath.

Fluidigm Files Patent Infringement Suit Against IONpath

Fluidigm Launches Breakthrough RNA Sequencing Library Preparation Workflow, Delivering Substantial Cost Savings and Efficiency Fluidigm Launches Breakthrough RNA Sequencing Library Preparation Workflow, Delivering Substantial Cost Savings and Efficiency

Fluidigm Revolutionizes Next-Generation Sequencing RNA Library Preparation with Microfluidic Automation

Fluidigm Showcases Immuno-Oncology Imaging Innovations at WMIC to Advance Translational and Clinical Cancer Research Fluidigm Showcases Immuno-Oncology Imaging Innovations at WMIC to Advance Translational and Clinical Cancer Research

Fluidigm Launches Imaging Mass Cytometry Immuno-Oncology Panel Kits and Advanced CyTOF Software at the 2019 World Molecular Imaging Congress (WMIC)

SOUTH SAN FRANCISCO, Calif., Aug.  20, 2019  (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that the company’s management will participate in two upcoming investor conferences.

Fluidigm to Participate in Upcoming Health Care Investor Conferences

Weakness in the legacy microfluidics business is offsetting the company's best growth opportunity. What needs to happen for that to change?

Fluidigm is Running in Place, but Expects to Break Out in 2020

The company reported second-quarter revenue at the low end of its expectations and well below the average Wall Street estimate.

Here's Why Fluidigm Is Getting Crushed Today

Fluidigm Corporation (FLDM) CEO Chris Linthwaite on Q2 2019 Results - Earnings Call Transcript

The decision to retire $150 million in convertible debt caught the market off guard, but the business made progress on its long-term goals.

Fluidigm Delivers Growth Where It Matters Most in Q1 2019

Fluidigm Corp (FLDM) CEO Stephen Linthwaite on Q1 2019 Results - Earnings Call Transcript

The laboratory equipment manufacturer announced first-quarter 2019 operating results and a significant transaction.

Here's Why Fluidigm Shares Fell as Much as 14.4% Today

Fluidigm (FLDM) delivered earnings and revenue surprises of -40.00% and 4.25%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Fluidigm (FLDM) Reports Q1 Loss, Tops Revenue Estimates

Better-than-expected performance at mass cytometry market and higher revenues is likely to aid Fluidigm's (FLDM) in Q1 earnings. However, sluggishness in microfluidics market remains a dampener.

News for Fluidigm Stock (FLDM)